Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators...
https://pubmed.ncbi.nlm.nih.gov/34351721/Actively Recruiting
Led by University of Manitoba · Updated on 2026-09-30
4000
Participants Needed
68
Research Sites
52 weeks
Total Duration
Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.
CONDITIONS
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
C
Chantale Pineau
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Manitoba
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Therapeutic‑dose Heparin | Usual Care |
|---|---|---|
| What it is | Therapeutic‑dose heparin (LMWH or UFH per protocol) given in hospitalized adults with CAP requiring supplemental oxygen | Usual care for hospitalized adults with CAP without therapeutic‑dose anticoagulation |
| Role in trial | Investigational treatment arm with therapeutic anticoagulation | Control arm receiving standard management without therapeutic anticoagulation |
| Primary use | To assess whether adding therapeutic‑dose heparin improves outcomes in non‑critically ill hospitalized CAP patients | Represents current standard management for CAP without therapeutic anticoagulation |
| How it is given or performed | LMWH based on measured or estimated weight; or IV UFH dosed per protocol to reach target aPTT or anti‑Xa level | Standard supportive care without therapeutic anticoagulation |
| Evidence status | Efficacy in CAP is under investigation, no results yet available | Standard supportive care remains the guideline‑recommended approach for CAP management |
| Important limitations | Safety and benefit in infection‑related pneumonia not yet established; study excludes critically ill and high‑bleeding‑risk patients | Does not assess impact of therapeutic anticoagulation; may not reflect potential benefits in subgroups |
| Patient impact | Not yet known; results pending | Reflects current standard recovery trajectories in CAP without added anticoagulation |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 14 days
Participants receive either therapeutic-dose heparin daily or usual care thromboprophylaxis. Treatment starts soon after randomization and continues for up to 14 days or until hospital discharge.
Daily dosing during hospitalization
Duration - Up to 180 days
Participants are monitored for outcomes including survival, bleeding, thrombotic events, mechanical ventilation use, mortality, hospital-free days, and quality of life up to 180 days after treatment.
Periodic assessments during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators...
https://pubmed.ncbi.nlm.nih.gov/34351721/University of Manitoba
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor